Related Experiment Videos
Correlation of glioma cell regression with inhibition of insulin-like growth factor 1 and insulin-like growth
1Department of Neurology, New York University School of Medicine, New York 10016, USA.
Abstract:
To explore the antitumor effect of insulin-like growth factor 1 (IGF-I) antisense RNA and the interaction of IGF-I with insulin-like growth factor-binding proteins (IGFBPs) in glioma cells, a recombinant retrovirus expressing IGF-I antisense RNA was constructed and introduced into C6 glioma cells. IGF-I antisense RNA reverses the transformed phenotype in glioma cells and inhibits glioma cell growth by blocking overexpression of endogenous IGF-I. Expression of IGFBP-2 is increased in glioma cells as compared with normal adult glial cells. IGF-I antisense RNA also inhibits expression of IGFBP-2 in glioma cells, but does not influence expression of the other IGFBPs. Although IGFBP-2 in conditioned medium from wild-type C6 cell cultures itself does not directly influence glioma cell growth, it synergistically enhances exogenous IGF-I-mediated DNA synthesis in IGF-I-negative C6 cells. These findings indicate the inhibitory effect of IGF-I antisense RNA on growth and development of glioma cells. IGF-I-dependent glioma cell growth may, in some circumstances, require IGFBP-2 as a cofactor. The antitumor effect of IGF-I antisense RNA is also associated with inhibition of IGFBP-2 expression.
Insights
Insulin-like growth factor 1 (IGF-I) antisense RNA inhibits glioma cell growth by blocking IGF-I and IGFBP-2 expression. This provides a potential new strategy for treating gliomas.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Glioma cell growth is often driven by insulin-like growth factor 1 (IGF-I).
- Insulin-like growth factor-binding proteins (IGFBPs), particularly IGFBP-2, play a role in glioma development.
- Understanding the interplay between IGF-I and IGFBPs is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the antitumor effects of IGF-I antisense RNA in glioma cells.
- To explore the interaction between IGF-I and IGFBPs in the context of glioma.
- To determine the role of IGFBP-2 in IGF-I-mediated glioma cell proliferation.
Main Methods:
- Construction and introduction of a recombinant retrovirus expressing IGF-I antisense RNA into C6 glioma cells.
- Assessment of glioma cell phenotype, growth, and expression levels of IGF-I and IGFBPs (including IGFBP-2).
- Evaluation of the effects of IGFBP-2 and exogenous IGF-I on glioma cell DNA synthesis.
Main Results:
- IGF-I antisense RNA reversed the transformed phenotype and inhibited growth of C6 glioma cells by blocking endogenous IGF-I overexpression.
- Expression of IGFBP-2 was significantly increased in glioma cells compared to normal glial cells and was inhibited by IGF-I antisense RNA.
- While IGFBP-2 alone did not affect glioma cell growth, it synergistically enhanced exogenous IGF-I-mediated DNA synthesis in IGF-I-negative cells.
Conclusions:
- IGF-I antisense RNA demonstrates significant antitumor effects against glioma cells.
- The antitumor activity is associated with the inhibition of both IGF-I and IGFBP-2 expression.
- IGFBP-2 may act as a cofactor in certain circumstances of IGF-I-dependent glioma cell growth, highlighting its potential as a therapeutic target.